Compare COHN & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COHN | CCEL |
|---|---|---|
| Founded | 1999 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Managed Health Care |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3M | 32.7M |
| IPO Year | N/A | 1997 |
| Metric | COHN | CCEL |
|---|---|---|
| Price | $18.24 | $3.41 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 32.8K | 14.0K |
| Earning Date | 03-09-2026 | 02-27-2026 |
| Dividend Yield | 5.52% | ★ 11.83% |
| EPS Growth | ★ 6.29 | N/A |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $185,475,000.00 | $31,747,500.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.25 | ★ N/A |
| Revenue Growth | ★ 107.11 | N/A |
| 52 Week Low | $6.10 | $3.10 |
| 52 Week High | $32.60 | $8.79 |
| Indicator | COHN | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.88 | 38.45 |
| Support Level | $17.34 | $3.29 |
| Resistance Level | $19.25 | $3.57 |
| Average True Range (ATR) | 1.35 | 0.17 |
| MACD | -0.19 | 0.01 |
| Stochastic Oscillator | 29.58 | 20.52 |
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.